The clinician who ordered the panel was not concerned; I would still like to understand it.
I would like to set this up properly once, rather than adjust it repeatedly.
My budget is real but not tight, and my tolerance for uncertainty is low.
What would you do, and what would make you change course?
The honest position is that most people order too many analytes and too few time points, when the reverse would be more informative.
Delta checks — comparing against your own previous value — are far more sensitive than comparing against a population interval, which is the argument for keeping a series rather than a snapshot.
| Trial | Agent | n | Duration | Primary result |
|---|---|---|---|---|
| STEP 1 | Semaglutide 2.4 mg | 1,961 | 68 wk | −14.9 % vs −2.4 % weight |
| STEP 2 | Semaglutide 2.4 mg, T2DM | 1,210 | 68 wk | −9.6 % vs −3.4 % weight |
| SURMOUNT-1 | Tirzepatide 5/10/15 mg | 2,539 | 72 wk | −15 / −19 / −21 % weight |
| SURMOUNT-4 | Tirzepatide, withdrawal | 670 | 88 wk | Continued loss vs substantial regain |
| SELECT | Semaglutide 2.4 mg | 17,604 | ~40 mo | MACE HR 0.80 (0.72–0.90) |
| FLOW | Semaglutide 1.0 mg, CKD | 3,533 | ~3.4 yr | Renal composite reduced; stopped early |
| SURMOUNT-OSA | Tirzepatide, OSA | 469 | 52 wk | AHI reduced with and without PAP |
Haemolysis in the sample raises potassium and several enzymes spuriously. If a result is bizarre, ask whether the sample was flagged before building a theory on it.
Biological variation data are published per analyte and are the basis for the reference change value — the difference between two results that is larger than noise.
Research-use compounds are not approved for human use, and no panel makes that safer.
Decide the action for each result before you order the test.
Analytical standards and reagents with traceable certificates. Every quantitative result you read inherits the accuracy of the standard behind it.
Shop standardsAnswering this needs to distinguish screening from monitoring. A screening panel looks for the unexpected; a monitoring panel tracks something you already have a reason to watch.
Timing matters per analyte: cortisol and testosterone are diurnal, triglycerides are postprandial, and creatinine responds to hydration and to recent training. Fixing the conditions removes most of the noise.
Keep the reports rather than the numbers. Units, reference intervals and methods all vary, and a bare number two years later is not comparable to anything.
External quality assurance schemes document between-laboratory differences on common analytes that routinely exceed the size of clinically interesting changes.
The caveat is that a panel is not a diagnosis and interpreting one is a clinician's job, particularly when several values move together.
Keep the full report, not the number. You will need the units and the interval later.
edited 4 Nov 2024 by lipid_panel_q — removed a claim I could not source
Start with a baseline. A result taken before anything started converts most later ambiguity into a simple comparison, and it cannot be obtained retrospectively.
Same laboratory, same method, same time of day, same fasting state. Between-laboratory differences on several common analytes are larger than the changes people are trying to detect.
Specifically, a twenty-analyte panel run on a healthy person will produce, on average, one out-of-range result purely from how reference intervals are constructed. That is arithmetic rather than pathology.
Pre-analytical factors — posture, tourniquet time, fasting, sample handling — are the largest source of error in routine biochemistry, well ahead of the analysis itself.
Same laboratory, same time, same fasting state, or the comparison is not a comparison.
Answer first: decide what you would do differently for each possible result before you order the panel. Anything that fails that test is a number you will worry about and not act on.
A sensible core for this population is a full blood count, renal function with electrolytes, liver enzymes with bilirubin, a fasting lipid panel with apolipoprotein B, HbA1c and thyroid-stimulating hormone.
Reference intervals are conventionally the central ninety-five per cent of a reference population, which is the direct cause of the one-in-twenty out-of-range rate on a healthy panel.
Baseline first, then a repeat under identical conditions. Everything else is secondary.
Standardise the conditions — same time of day, same fasting state, same laboratory — or you are measuring the conditions rather than yourself.
Repeat before you react. A single abnormal value has a substantial probability of being within the combined biological and analytical variation of a normal one.
One out-of-range value on a twenty-analyte panel is expected. Two on a repeat is a finding.
Ask PeptideStack is a static archive. Posting is closed, but the norms are worth stating: answer the question that was asked, show your working, cite the trial or the certificate, and say plainly where the evidence runs out.